key: cord-0935524-tmg4geal authors: Guo, Sheng; Xie, Hang; Lei, Yu; Liu, Bin; Zhang, Li; Xu, Yechun; Zuo, Zhili title: Discovery of Novel Inhibitors Against Main Protease (Mpro) of SARS-CoV-2 via Virtual Screening and Biochemical Evaluation date: 2021-02-24 journal: Bioorg Chem DOI: 10.1016/j.bioorg.2021.104767 sha: 49631a38e7907688473c7caf0343308a53cd411b doc_id: 935524 cord_uid: tmg4geal SARS-CoV-2 is the pathogen that caused the global COVID-19 outbreak in 2020. Promising progress has been made in developing vaccines and antiviral drugs. Antivirals medicines are necessary complements of vaccines for post-infection treatment. The main protease (Mpro) is an extremely important protease in the reproduction process of coronaviruses which cleaves pp1ab over more than 11 cleavage sites. In this work, two active main protease inhibitors were found via docking-based virtual screening and bioassay. The IC50 of compound VS10 was 0.20 μM, and the IC50 of compound VS12 was 1.89 μM. The finding in this work can be helpful to understand the interactions of main protease and inhibitors. The active candidates could be potential lead compounds for future drug design. At the end of 2019, a coronavirus that swept the world was named SARS-CoV-2 by the International Committee on Taxonomy. The disease caused was named COVID-19 by the World Health Organization 1 . SARS-CoV-2 has a strong infectious ability that seriously threatening human life worldwide. This kind of virus can cause diseases in humans and infect mammals [2] [3] [4] , and the infected people or animals may become carriers of respiratory, intestinal, liver, and nervous system diseases 5 polyprotein 1a (pp 1a) and polyprotein 1ab (pp 1ab). These polyproteins are processed by the main protease (Mpro), also known as 3C-like protease (3CLpro), and one or two papain-like proteases (PLP) to become 16 non-structural proteins (nsps) 11 . These nsps are involved in the production of subgenomic RNA, which encodes four major structural proteins, namely surface spike glycoprotein (S), envelope protein (E), membrane protein (M) and Nucleocapsid protein (N) 12, 13 . Then proteins are collected with new RNA genome assembly in the endoplasmic reticulum (ER) and Golgi- Mpro plays a vital role in the replication cycle of the coronavirus, because the Mpro operates at more than 11 cleavage sites on the pp1ab 15 In this work, we tried to identify the inhibitors of Mpro by docking-based virtual screening and the biochemical evaluation against the Specs database. Then, we explored and compared the interaction modes between compounds obtained and known Mpro inhibitors. This work tried to provide a rapid discovery of Mpro inhibitors which could be developed as drug lead compound against the SARS-Cov-2. In this work, docking-based virtual screening and biochemical evaluation were carried out to discover potential Mpro inhibitors. The three-dimensional crystal structure of Mpro of SARS-CoV-2 has been extracted from PDB database (PDB code: 6LU7; resolution: 2.16 Å) 20 . The working flow for this work is shown in Figure 1 . Discovery Studio 4.0 (DS 4.0) was employed to prepare protein by adding missing residues, hydrogen atoms as well as removing water molecules and spectator ions 21 . Then, the structure was minimized and optimized using Maestro 12.3 software (www.schrodinger.com) with OPLS3e force field. The physical condition of PH was set as 7.0. This step optimized the structure, to relieve any strain and fine-tune the placement of various groups. Hydrogen atoms are always optimized fully, which allows relaxation of the H-bond network. Heavy atoms were optimized with converge of 0.3 Å. Allowing movement of the heavy atoms can relieve structural strain, but will result in some deviation from the initial crystal structure. The 212,736 molecules from the Specs database (http://www.specs.net) were filtered by Lipinski and Veber rules, and 75,671 molecules were retained 22 . A PAINS (pan assay interference compounds) filtering was employed to remove false positive compounds using FAFDrugs4 (https://fafdrugs4.rpbs.univ-paris-diderot.fr/) 23 The Dock Ligands (LibDock) protocol is developed by Diller and Merz 26 . The binding site was defined by the position of original ligand. The protein site features used in LibDock is referred to as Hot Spots (polar and apolar). A polar Hotspot is preferred by a polar ligand atom, for example, a hydrogen bond donor or acceptor. An apolar Hot Spot is preferred by an apolar atom, for example, a carbon atom. The receptor Hot Spot file is calculated prior to the docking procedure. The rigid ligand poses were put into the active site and Hot Spots are matched as triplets. The poses are pruned and a final optimization step is performed before the poses were scored. GOLD (https://www.ccdc.cam.ac.uk) was selected for precise docking simulation of ligands from previous step. GOLD can make high database enrichments and identify the correct binding mode reliably. The retained candidates by LibDock were further screened using the GOLD docking program 27, 28 . At the same time, 8 published Mpro inhibitors were selected as templates to do structure similarity screening in Specs 11, 29 , exhibited in Table 2. There were 3 templates and 3 scoring functions available to evaluate the quality of the docking. The binding pocket was defined within 7 Å from the co-crystallised ligand. The co-crystallised ligand was docked back to the binding pocket to find the most suitable score function. The combination of goldscore_p450_csd and CHEMPLP gave the highest score (117.86) and low RMSD (2.5498Å) as illustrated in Table 1 . They were thus selected for docking simulation. The value of GA runs was set to 50 times. Due to some molecules share the similar skeleton, Cluster Ligands was used to reduce repeatability and increase the hit rate. The remaining molecules were purchased for the biochemical evaluation. The protein expression and purification of SARS-CoV-2 Mpro has previously been described 11, 30 . In brief, the cDNA of full-length SARS-CoV-2 Mpro (GenBank: for the enzymatic inhibition assay. The inhibition assay of SARS-CoV-2 Mpro has previously been described 30 The final selected 37 molecules were tested by biochemical evaluation, from which 2 compounds showed relative high biological activity ( Figure 3 and Table 3 ). The IC 50 of compound VS10 is 0.20μM, and the IC 50 of compound VS12 is 1.89μM. 1.89 ± 0.22 We analyzed the interaction between these two small molecules and protein via DS 4.0, Pymol 2.2.3 and online server (https://projects.biotec.tu-dresden.de/plipweb/plip/index) 31 . Shown as Figure 4 (A), the CO of compound VS10 formed four strong hydrogen bonds with GLY143, SER144 and CYS145. In addition, the SH of CYS145 also formed two weak hydrogen bonds with benzene ring and heterocycle. MET165 and GLU166 formed a hydrogen bond with two benzene rings, respectively. As presented in Figure 4 ( N3 inhibitor simultaneously acts on S1, S2, S4 and S1' subsites, as well as 11a and 11b. These small molecules have more interactions with Mpro, which makes them more stable together and shows a better inhibitory effect. VS10 acts on S1, S4 and S1' subsites, while VS12 acts on S1, S2, S4 and S1' subsites. Figure 5 , and Figure 6 ). The results showed that the inhibitory activity of VS10 remained unchanged with the prolongation of incubation time (Table 4 and Figure 5 ). However, the inhibitory activity of VS12 against SARS-CoV-2 Mpro increased with the prolongation of incubation time (Table 4 and Figure 6 ). Contrary to the stable IC 50 of VS10, the IC 50 of VS12 decreases as the incubation time increases. Therefore, we suspected that VS12 reacted with one or more cysteines and was the covalent inhibitor of SARS-CoV-2 Mpro. No matter what kind of interaction, the docking results show that the interaction sites are close to CYS145 ( Figure 4 ). To shown good inhibitory activity. The binding modes of the two molecules were analyzed, which has shown that the drug leads identified can bind to the binding pocket of SARS-CoV-2 Mpro. HIS41, CYS145, MET165 and GLU166 are found to be the potential amino acids for inhibitor binding. In this study, the virtual screening and highthroughput screening proved to be efficient strategies to discover antiviral leads against SARS-CoV-2 virus. The methods presented here can be greatly helpful in the rapid discovery of drug leads from a large compound library against new emerging infectious diseases which currently lack specific medicines. and Coronaviridae Study Group of the International Committee on Taxonomy of, V. (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 SARS and MERS: recent insights into emerging coronaviruses Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2 Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility A glimpse into the eye of the COVID-19 cytokine storm Commentary: Origin and evolution of pathogenic coronaviruses Origin and evolution of pathogenic coronaviruses A Novel Coronavirus from Patients with Pneumonia in China Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus Emerging coronaviruses: Genome structure, replication, and pathogenesis Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Screening for natural and derived bioactive compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic silico Drug Discovery of Major Metabolites from Spices as SARS-CoV-2 Main Protease Inhibitors Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors Identification of bioactive molecules from Tea plant as SARS-CoV-2 main protease inhibitors Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs Structural Analysis of COVID-19 Main Protease and its Interaction with the Inhibitor N3 Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants Discovery of novel wee1 inhibitors via structure-based virtual screening and biological evaluation The FAF-Drugs2 server: A multistep engine to prepare electronic chemical compound collections ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development Assessment of the Oral Rat Chronic Lowest Observed Adverse Effect Level Model in TOPKAT, a QSAR Software Package for Toxicity Prediction High throughput docking for library design and library prioritization Development and validation of a genetic algorithm for flexible docking A genetic algorithm for flexible molecular overlay and pharmacophore elucidation Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients PLIP: Fully automated protein-ligand interaction profiler Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Highlights Two active Mpro inhibitors of SARS-CoV-2 were discovered via docking-based virtual screening and bioassay The IC 50 of compound VS10 was 0.20 μM, and the IC 50 of compound VS12 was 1.89 μM VS12 may interact Mpro via covalent bond No potential conflict of interest was reported by the authors.